Predictive factors of herpes zoster HIV-infected patients: another adverse effect of crack cocaine.
A retrospective cohort study was conducted on 1541 HIV-infected patients to determine variables associated with the incidence of herpes zoster. A single failure Cox model showed that herpes zoster incidence increased following the first 6 months of antiretroviral treatment adjusted hazard ratio (AHR)=5 (95%CI=2.6-9.2), P<0.001; in the >60 years age group AHR=2 (95%CI=1-4), P=0.04; in patients in the top CD8 quartile AHR=2.1 (95%CI=1.3-3.6), P<0.001; and in patients previously reported to use crack cocaine AHR=5.9, (95%CI=1.4-25), P=0.02. Herpes zoster incidence increased in patients with CD4 counts<500 per mm(3) and gradually declined since 1992-1996, with AHR=0.3 (95%CI=0.2-0.5), P<0.001 for the 1997-2002 period and AHR=0.24 (95%CI=0.14-0.4), P<0.001 for the 2002-2008 period. Contrary to what has been described elsewhere, there was no specific effect of protease inhibitors on herpes zoster incidence. The present study is the first to suggest that crack cocaine is associated with an increased incidence of herpes zoster. The neurological or immunological effects of crack are discussed.
Centre d'Investigation Clinique Epidémiologie Clinique Antilles Guyane (INSERM / DGOS CIE 802), Centre Hospitalier de Cayenne, Cayenne, French Guiana ; Epidemiologie Parasitoses et Mycoses Tropicales, EA 3593, Université Antilles Guyane, and COREVIH Guyane, Cayenne, French Guiana ; Centre Hospitalier de Cayenne, Cayenne, French Guiana.
Mathieu
M
Nacher
Celia
C
Basurko
Antoine
A
Adenis
Emilie
E
Gaubert-Marechal
Emilie
E
Mosnier
Sophie
S
Edouard
Vincent
V
Vantilcke
Sindou
S
Sivapregassam
Benoit
B
Tressières
André
A
Cabié
Pierre
P
Couppié
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000473:pathology / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000473:pathology / Q000821:virology; D019970:Cocaine-Related Disorders / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D016578:Crack Cocaine / Q000009:adverse effects*; D005260:Female; D006678:HIV / Q000187:drug effects / Q000502:physiology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy / Q000473:pathology / Q000821:virology; D014645:Herpesvirus 3, Human / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011480:Protease Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D019562:Viral Load / Q000187:drug effects; D014775:Virus Activation / Q000187:drug effects*
D019380:Anti-HIV Agents; D016578:Crack Cocaine; D011480:Protease Inhibitors